Shares of Geron Co. (NASDAQ:GERN) have been assigned an average recommendation of “Buy” from the eight ratings firms that are covering the stock, MarketBeat reports. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and six have given a buy rating to the company. The average 1-year price target among analysts that have updated their coverage on the stock in the last year is $3.90.
A number of equities analysts recently issued reports on the stock. HC Wainwright assumed coverage on shares of Geron in a research note on Tuesday, September 3rd. They issued a “buy” rating and a $4.00 price target on the stock. B. Riley upped their price target on shares of Geron from $3.25 to $4.50 and gave the stock a “buy” rating in a research note on Friday, June 28th. ValuEngine upgraded shares of Geron from a “hold” rating to a “buy” rating in a research note on Saturday, August 10th. Cantor Fitzgerald started coverage on Geron in a research report on Thursday, August 15th. They issued an “overweight” rating and a $4.00 target price for the company. Finally, BidaskClub lowered Geron from a “hold” rating to a “sell” rating in a research report on Friday, September 27th.
A number of large investors have recently modified their holdings of the business. DekaBank Deutsche Girozentrale raised its position in Geron by 64.0% in the 2nd quarter. DekaBank Deutsche Girozentrale now owns 41,000 shares of the biopharmaceutical company’s stock worth $62,000 after buying an additional 16,000 shares during the last quarter. Rudd International Inc. purchased a new position in Geron in the 2nd quarter worth about $30,000. Tower Research Capital LLC TRC raised its position in Geron by 482.4% in the 2nd quarter. Tower Research Capital LLC TRC now owns 29,801 shares of the biopharmaceutical company’s stock worth $42,000 after buying an additional 24,684 shares during the last quarter. Charles Schwab Investment Management Inc. raised its position in Geron by 3.0% in the 2nd quarter. Charles Schwab Investment Management Inc. now owns 1,080,623 shares of the biopharmaceutical company’s stock worth $1,524,000 after buying an additional 31,448 shares during the last quarter. Finally, Wells Fargo & Company MN raised its position in Geron by 38.9% in the 2nd quarter. Wells Fargo & Company MN now owns 128,235 shares of the biopharmaceutical company’s stock worth $181,000 after buying an additional 35,925 shares during the last quarter. 31.16% of the stock is owned by institutional investors and hedge funds.
Geron (NASDAQ:GERN) last announced its quarterly earnings results on Thursday, August 1st. The biopharmaceutical company reported ($0.08) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.09) by $0.01. The company had revenue of $0.10 million for the quarter, compared to analysts’ expectations of $0.20 million. Geron had a negative net margin of 5,328.80% and a negative return on equity of 22.33%. On average, analysts forecast that Geron will post -0.43 EPS for the current year.
Geron Corporation, a clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for hematologic myeloid malignancies. The company supports the clinical stage development of imetelstat, a telomerase inhibitor for the treatment of hematologic myeloid malignancies.
Recommended Story: Initial Coin Offering (ICO)
Receive News & Ratings for Geron Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Geron and related companies with MarketBeat.com's FREE daily email newsletter.